N
Nintx
Startup with innovation as core business, based on advanced technologies to develop the next generation of therapies
About Nintx
Nintx is a Brazilian startup that operates in the biotechnology sector, leveraging the country's rich biodiversity to develop therapeutic solutions. The company combines advanced technologies, top professionals, and strong partnerships to create a scalable platform for drug discovery and development. Nintx's primary focus is on microbiome-derived therapies and natural products-based drug discovery, using advanced analytical, 'omics', and screening technologies, supplemented by data science and analytics methodologies.
The company's target market includes the global pharmaceutical and biotechnology industries, which are always in search of innovative therapeutic solutions. Nintx's business model is centered around the research, development, and commercialization of novel therapies derived from Brazil's biodiversity. The company generates revenue through the development and sale of these therapeutic solutions.
Nintx operates in a favorable environment, with Brazil's advanced legal and regulatory framework for accessing biodiversity playing a significant role. The company's leadership believes that Nintx is well-positioned to become a key player in the global research and development arena, leveraging its unique approach to drug discovery and development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- São Paulo, Brazil
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 70.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Dec 2024 | $10M | $40M | Pitanga Fund · MOV Investimentos · Ecoa Capital · Adeste | ↗ |
| SEED✓Equity / VC | Sep 2022 | $532K | $2.1M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Nintx is 880 monthly website visits, down 51.1% over the last three months. Nintx's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Pitanga Fund
MOV Investimentos
Ecoa Capital
Adeste- GLGuilherme Leal
Laboratory Tiaraju- PAPeter Andersen
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nintx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nintx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.